NanoViricides, Inc. (NNVC)
| Previous Close | 1.1750 |
| Open | 1.1900 |
| Bid | 1.1000 x 3000 |
| Ask | 1.1200 x 4000 |
| Day's Range | 1.1000 - 1.1899 |
| 52 Week Range | 1.0000 - 2.0000 |
| Volume | |
| Avg. Volume | 36,854 |
| Market Cap | 13.075M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
ACCESSWIRENanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ...
- ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration ...
- ACCESSWIRE
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy ...
